Endra Life Sciences Inc Stock Price, News & Analysis

ENDRA Life Sciences (NASDAQ:NDRA) reported its Q1 2021 financial results, revealing a net loss of $2.3 million ($0.06 per share), an improvement from a loss of $3.3 million ($0.29 per share) in Q1 2020. Operating expenses decreased to $2.6 million from $3.1 million year-over-year. The company secured a total of $12.6 million through warrant exercises and its ATM facility. Significant advancements include partnerships with Hepion Pharmaceuticals and Inselspital University Hospital for clinical validation of the TAEUS system, aimed at assessing liver conditions. Cash reserves stood at $16.8 million as of March 31, 2021.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced it will report its first quarter 2021 financial results on May 17, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and recent corporate developments. ENDRA is known for its Thermo Acoustic Enhanced UltraSound (TAEUS®), a cost-effective ultrasound technology aimed at assessing liver conditions affecting over 1 billion individuals worldwide. More information can be found on their website.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced the issuance of two U.S. patents related to its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents include the '624 patent, which enhances TAEUS probe functionality, and the '163 patent, which protects the design of its thermoacoustic imaging probe. Both patents aim to improve diagnostic capabilities for conditions like Non-Alcoholic Fatty Liver Disease (NAFLD), affecting over 1 billion globally. ENDRA also highlighted its growing intellectual property portfolio, now at 85 assets, and ongoing clinical partnerships, especially with GE Healthcare.

ENDRA Life Sciences (NASDAQ:NDRA) will present its Thermo Acoustic Enhanced Ultrasound (TAEUS™) technology at the AIUM Annual Integrative Ultrasound Meeting on April 14, 2021, at 11:45 am ET. The presentation, led by CTO Michael Thornton, will overview TAEUS and its application in measuring liver fat, targeting conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) affecting over one billion people worldwide. ENDRA will also showcase its TAEUS liver system in a virtual booth from April 11 to April 25.

ENDRA Life Sciences (NASDAQ:NDRA) reported its financial results for Q4 and FY 2020, with a net loss of $2.3 million ($0.10/share) in Q4, down from $4.8 million in 2019. Total operating expenses decreased to $2.3 million from $3.1 million in Q4 2019. For the full year, net loss was $11.7 million ($0.63/share), improved from $13.3 million in 2019. The company secured partnerships and clinical studies in Europe, strengthened its intellectual property, and raised $18.5 million through stock sales. A call to discuss results was scheduled for 4:30 PM ET today.

ENDRA Life Sciences (NASDAQ:NDRA) has partnered with Hepion Pharmaceuticals (NASDAQ:HEPA) to integrate its innovative TAEUS technology into Hepion's Phase 2b trial for CRV431, targeting non-alcoholic steatohepatitis (NASH). This collaboration aims to enhance patient screening and biomarker measurement, providing a cost-effective and non-invasive method for liver fat assessment. Positive topline data has been reported from Hepion's Phase 2a AMBITION trial, with patient enrollment for the Phase 2b study set to commence in late 2021, signaling advancements in liver disease treatments.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will report its fourth quarter 2020 financial results on March 25, 2021, after market close. A conference call and webcast are scheduled for 4:30 p.m. Eastern time, allowing management to discuss the financial results and recent corporate updates. The company is known for its Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at diagnosing chronic liver conditions affecting over 1 billion people globally. The details for participation and access to a replay are included in the press release.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in two upcoming virtual investment conferences. The H.C. Wainwright Global Life Sciences Virtual Conference is scheduled for March 9-10, 2021, where management will give a presentation and hold one-on-one meetings. A recorded presentation will be available on demand from March 9, 2021. The 33rd Annual ROTH Conference will take place from March 15-19, 2021, with similar opportunities. ENDRA develops the Thermo Acoustic Enhanced UltraSound (TAEUS^®) technology, aiming to improve liver health diagnostics.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) has announced a new clinical study partnership with Inselspital University Hospital in Bern, Switzerland, focusing on the TAEUS ultrasound device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD). This collaboration marks ENDRA's third clinical research partnership in Europe and aims to validate TAEUS as a non-invasive alternative to more invasive diagnostic techniques, involving 75 patients. The study data will enhance clinical evidence for TAEUS as commercialization efforts advance in Europe, alongside a recent collaboration renewal with GE Healthcare.